CIK 0000818033
- Accelerated filer
HERON THERAPEUTICS, INC. /DE/
Sign in to watch- Ticker
- HRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 942875566
- Phone
- +1 858-251-4400
- Business address
- 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA, 92121
- Former names
- AP PHARMA INC /DE/, ADVANCED POLYMER SYSTEMS INC /DE/
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-12-19 | Quart Barry D Chief Executive Officer | Grant or award · Employee Stock Option (Right to Buy) | +325,000 | 325,000 | ||
| 2019-12-19 | POYHONEN JOHN EVP, Chief Commercial Officer | Grant or award · Employee Stock Option (Right to Buy) | +55,562 | 55,562 | ||
| 2019-12-19 | MANHARD KIMBERLY Executive VP, Drug Development | Grant or award · Employee Stock Option (Right to Buy) | +120,000 | 120,000 | ||
| 2019-12-19 | HOFFMAN ROBERT CFO & SVP, Finance | Grant or award · Employee Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2019-12-19 | Christian Waage Director | Grant or award · Stock Option (Right to Buy) | +17,000 | 17,000 | ||
| 2019-12-19 | Johnson Craig A Director | Grant or award · Stock Option (Right to Buy) | +23,000 | 23,000 | ||
| 2019-12-19 | DAVIS STEPHEN Director | Grant or award · Stock Option (Right to Buy) | +15,500 | 15,500 | ||
| 2019-12-19 | TANG KEVIN C Director | Grant or award · Stock Option (right to buy) | +17,000 | 17,000 | ||
| 2019-11-29 | MANHARD KIMBERLY Executive VP, Drug Development | Exercise or conversion | +24,000 | $13.00 | $312K | 24,000 |
| 2019-11-29 | MANHARD KIMBERLY Executive VP, Drug Development | Sale | −24,000 | $26.00 | $624K | 0 |
| 2019-11-29 | MANHARD KIMBERLY Executive VP, Drug Development | Exercise or conversion · Employee Stock Option (Right to Buy) | −24,000 | 58,416 | ||
| 2019-10-04 | TANG KEVIN C Director | Purchase | +285,714 | $17.50 | $5.0M | 5,799,810 |
| 2019-10-03 | Quart Barry D Chief Executive Officer | Purchase | +4,571 | $17.50 | $80K | 94,652 |
| 2019-10-03 | POYHONEN JOHN EVP, Chief Commercial Officer | Purchase | +5,143 | $17.50 | $90K | 18,143 |
| 2019-10-01 | DAVIS STEPHEN Director | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2019-10-01 | DAVIS STEPHEN Director | Grant or award · Stock Option (Right to Buy) | +750 | 750 | ||
| 2019-07-15 | POYHONEN JOHN EVP, Chief Commercial Officer | Grant or award · Employee Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2019-05-22 | POYHONEN JOHN Director | Purchase | +3,000 | $17.55 | $53K | 13,000 |
| 2019-05-15 | Christian Waage Director | Purchase | +1,400 | $18.04 | $25K | 1,400 |
| 2019-05-01 | MANHARD KIMBERLY Executive VP, Drug Development | Sale | −1,109 | $18.86 | $21K | 0 |
Page 30 of 38 · 746 trades